Search results
Added:
3 years ago
Heart failure (HF) affects more than 6 million people in the US and results in more than 1 million hospitalisations per year.1 In patients aged ≥65 years, there are more hospitalisations for a primary diagnosis of HF than any other condition.2 HF is a debilitating illness, associated with significant morbidity and mortality, rehospitalisation and societal costs.3 Current guidelines and position…
View more
Added:
3 years ago
The left ventricular ejection fraction (LVEF) – calculated as the stroke volume (end-diastolic volume minus end-systolic volume) divided by the end-diastolic volume – remains the main driver for categorising heart failure (HF) and it is a cornerstone in all randomised clinical trials for patients with HF. Although LVEF has many acknowledged limitations, it remains key for the classification,…
View more
Added:
4 months ago
Added:
1 year ago
BCIS ACI 2023 – Dr Angela Hoye (Hull & East Yorkshire Hospitals, UK), is joined by Dr Rod Stables (Liverpool Heart and Chest Hospital, UK), Dr Anthony Mathur (Barts Health NHS Trust, UK) and Dr Sen Devadathan (Royal Cornwall Hospitals NHS Trust, UK) to have a critical discussion on the BCIS-REVIVED trial and what it means for patients with ischemic left ventricular dysfunction in 2023.
Data…
View more
Added:
12 years ago
Left ventricular ejection fraction (LVEF) is one of the most commonly reported measures of left ventricular (LV) systolic function. It is the ratio of blood ejected during systole (stroke volume) to blood in the ventricle at the end of diastole (end-diastolic volume). If the LV end-diastolic volume (EDV) and end-systolic volume (ESV) are known, LVEF can be determined using the following equation:…
View more
Added:
3 years ago
The term cardiac remodelling (REM) is used to define changes that produce geometrical rearrangement of the normal structures of the heart, together with complex biological and molecular alterations. REM affects the heart at the level of the cardiomyocyte, the blood vessels and the extracellular matrix. Proliferation of the latter, resulting in fibrosis, is one of the hallmarks of pathological REM…
View more
Added:
3 years ago
Major advances in heart failure (HF) management have been achieved over the past three decades, yet it remains a syndrome with high morbidity and mortality, poor quality of life and high healthcare costs. Despite all advances in medical/device therapy, many HF patients continue to deteriorate, leading to poor quality of life and high rehospitalisation and mortality rates.1 The recent European…
View more
Added:
3 years ago
In the past few decades, tremendous developments have been made in the field of interventional cardiology. The evolution of such tools as balloon angioplasty, bare-metal stents (BMS) and now drug-eluting stents (DES) has incrementally opened up new possibilities in the treatment of coronary artery disease and, correspondingly, an ever-decreasing need for invasive surgery. The most challenging…
View more
Added:
3 years ago
Topic: Heart Failure (Clinical), Cardiomyopathy, Myocarditis
Background
The mortality of heart disease has been increasing in all over the world. Cardiac hypertrophy is an important risk factor for heart failure. We have previously reported that protein arginine methyltransferase 5 (PRMT5) specific inhibitor EPZ015666 (EPZ) suppressed cardiomyocyte hypertrophy in neonatal rat cardiomyocytes…
View more
Added:
6 months ago
